- Home
- TJX vs NVO Comparison
TJX vs NVO Comparison
Compare TJX & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TJX | NVO |
|---|---|---|
| Founded | 1962 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | 69500 |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.6B | 197.4B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | TJX | NVO |
|---|---|---|
| Price | $155.52 | $47.66 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 16 | 11 |
| Target Price | ★ $169.00 | $51.00 |
| AVG Volume (30 Days) | 4.7M | ★ 11.9M |
| Earning Date | 05-20-2026 | 05-06-2026 |
| Dividend Yield | 1.23% | ★ 3.19% |
| EPS Growth | ★ 14.32 | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $29,078,407,000.00 | N/A |
| Revenue This Year | $6.75 | N/A |
| Revenue Next Year | $5.81 | $3.70 |
| P/E Ratio | $130.23 | ★ $13.60 |
| Revenue Growth | ★ 6.04 | N/A |
| 52 Week Low | $119.84 | $35.12 |
| 52 Week High | $170.00 | $71.80 |
Technical Indicators
Market Signals| Indicator | TJX | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 38.55 | 65.41 |
| Support Level | $153.17 | $47.52 |
| Resistance Level | $159.67 | $47.79 |
| Average True Range (ATR) | 3.92 | 1.32 |
| MACD | -1.14 | 0.47 |
| Stochastic Oscillator | 8.55 | 87.39 |
Price Performance
Historical ComparisonAbout TJX TJX Companies Inc. (The)
Founded in 1987, TJX Companies is the world's largest off-price apparel and home fashions retailer, operating more than 5,000 stores across nine countries. In fiscal 2026, the company generated roughly $60 billion in sales. TJX operates through four segments: Marmaxx (61% of sales), HomeGoods (17%), TJX Canada (9%), and TJX international (13%). Its off-price model emphasizes branded merchandise at meaningful discounts, driving high traffic and rapid inventory turnover.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.